The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
P&L not expected to be favourable first half. Full year should end comfortably cash positive based on £1million coming in from Solvay 2nd half. EPA info would be helpful and possibly game changing sooner or later.
P&L not expected to be favourable first half. Full year should end comfortably cash positive based on £1million coming in from Solvay 2nd half. EPA info would be helpful and possibly game changing sooner or later.
Beaphar launch Byotrol based pet products round the EU, starting well in Germany. In line with strategy of scientific evidence/proof, superior quality and within/meeting regulations. .....We [Beaphar] selected Byotrol as a key technology partner due to their scientific credentials and we look forward to developing our relationship further in the future.”
Byotrol are delighted to announce that they have agreed a partnership with the University of Chester to extend their hand sanitiser testing capabilities at Thornton Science Park facility. The partnership will support the development and testing of antimicrobial products which are required to pass the EN European standard tests, and will lead to students from the University assisting Byotrol with the protocol. thornton-science-park The use of hand sanitizers as part of a daily routine in health care, janitorial and consumer scenarios considerably reduces the occurrence and transmission of diseases both in the developed and the developing world. The World Health Organization actively promotes the use of such products and see it as one of the most accessible forms of reducing mortality rates arising from poor hygienic conditions in the developing world. Also it was reported in 2012 that MRSA related infections were the underlying factor in 9000 deaths in the UK, and it is estimated that 300,000 patients a year in England are affected by a health care associated infection with an annual cost of £1bn to the NHS. Byotrol currently market hand sanitiser products in Europe, USA and Japan and have only recently submitted a new patent application in this sector. The ongoing changes in regulations in Europe (Biocidal Product Regulation), together with the expansion of Byotrol’s portfolio of new formats in other parts of the world, leads to a constant pipeline of product reformulation which requires complementary laboratory antimicrobial testing on a daily basis. This partnership will enable Byotrol to improve and optimise this activity whilst introducing students to the rigours of commercialising antimicrobial products. The partnership between Byotrol and the University of Chester will continue the development of new scientific research and innovation at Thornton Science Park which has a unique blend of industry, innovation and academia making it an ideal location for a developing company like Byotrol.
'Old soap' is not what its about, for sure. Message here highlights USP being quality of product especially relating to regulations - being regulated, with added quality, where others fail to (or can't) keep up to date and have less evidence of efficacy/safety etc is the strategy and USP. Note from Byotrol re recent patent: 'The regulatory framework for the use of different biocides is constantly changing and so we are constantly investigating new technology platforms which give us differentiated and superior claims platforms. In particular the introduction of the Biocide Product Regulations (BPR) in Europe will mean that we need to modify formulations in the hand sanitisers sector and so we have taken this opportunity to introduce a new patented formulation which will enable us to build on the [existing] products.......' 'As we launch these products in 2017 we will be able to share more information about the products and their value proposition'
25p my have been naive on back of what was a unique scientific creation and the ability to sell it. The 80P was, I believe, when the science was popular during a flu epidemic or some bug scare of the time. Then it faded away and when potential crisis was over Byotrol was back looking for a way to sell. Fascinating science for most people but no compelling purpose very obvious. Now it is only about EPA [demand is high if EPA succeeds according to the Board], Kyorin etc hand sanitiser and Solvay Polymers. These have to deliver. There are many other opportunities but presently irrelevant. While 'longlasting' & 'alcohol/bleach free' etc were before of not much commercial interest, as you say yourself, its out there now. So which product is the most reliable and of highest quality?? Its Byorol. Thats the USP. High quality. [Quality meaning hitting the spot directly with minimum/least waste] Other products will not meet regs or not prove themselves worthy scientifically and will fall. Kyorin, for example, went for the scientifically proven quality. Kyorin is a sales crazy company i.e. Byotrol has now getting big global company marketing support. This is how it will sell now and was needed at 25P. So we wait to hear of more big deals - or not. Needs to generate income .......
Needlers @NeedlersPPE The latest in hygiene innovation from our supplier @byotrol November 3rd.
http://www.byotrol.co.uk/wp/wp-content/uploads/Byotrol-Kyorin-partnership-Oct-20161.pdf
Morning Schroder, Profitable consumer sector [B2B;B2C] revenue flow needed from 2 or 3 significant deals - bottom line for meaningful share price. And speculative confidence therein. When to buy? Pass. Have a good day. IMB
David Bullen, ex CEO of Anpario (natural feed additives for livestock), is consulting for Byotrol. Anpario.com.
Byotrol is in the NHS after-all! 120 NHS Trusts. 20 added this year. Byotrol CEO in regular communication. Athenian Hygiene @AthenianHygiene Over 120 #NHS trusts use Athenian as their brand of choice. Better value, safer and alcohol-free. Why use anything else? 7:13 am - 27 Sep 2016
The news flow {http://www.kyorin-pharm.co.jp/en/news/] on Kyorin does not yet include Byotrol - worth a look when they start selling the product end of year. Come across them before. An ambitious company, keen on alliances and very focused on sales. This unavoidably lengthy news-link describes there interest in Byotrol via another product the marched up with. http://www.kyorin-pharm.co.jp/en/news/docs/%EF%BC%88%E8%8B%B1%E8%AA%9E%EF%BC%89%E3%83%AB%E3%83%93%E3%82%B9%E3%82%BF0212.pdf Solvay, Kyorin and EPA. 3 deals. Enough? Here endeth AGM!
Might add Solvay deals, depending on who does what for products that are worked together, vary from a share of 25% to 50% for Byotrol - even with substantial donations made by Solvay. Certainly sounds good. Re-confirmed that Solvay are interested in the biocide world and how it how can work innovatively with their polymers but do not want to have to start a biocide division to find out. Makes sense. Maybe, they have found out already. Again, reiterated that the partnership is operating at the highest level of the Solvay organisation and its high level customers. I think it was expressed that Solvay might be interested in widening the geography yet further...? Solvay, Kyorin, EPA, non-alcohol sanitisers and committed athletes all emerged swiftly and active in short/medium term. More deals being chased up as per usual.
Another AGM, this time in Finncap, London. Resolutions accepted, an insightful presentation followed. There is enough cash in hand and Ebitda looking to break even, as it were. This from another cash insert from Solvay - previously £1miilion according to Finncap - in 2nd half of financial year and more consumer income to offset legacy professional shortfalls. On the latter there is a plan to turn that sector round - it still generates, or can generate, operating profit for the overheads and CEO does in fact see a significant 'golden' opportunity. The CEO was candid enough to state that the EPA tests outstanding are modest and are not 'make or break' so we can expect a positive result end of October and filed in Novemeber. Hopefully, we will then hear more of the interest in the product from potential US partners in the following months. The real USP of all the products is their high quality and accordingly having the ability to meet any and all regulations. 3 separate platforms are in place with and without the challenging ingredients within the EU. There is a lot of interest now in alcohol free hand sanitisers - not all competitive products will meet the changing regulations. As the regulations are activated the potential increases. It was further told that there is indeed a lot of interest in the world of sport. Cyclists and others used it at RIO and having returned safe and sound are showing their gratitude by sharing and recommending it to other sportsmen and sportswomen and other sports. The idea that the products lasts effectively for up to 6 hours is not necessarily fully recognised by sports consumers. But it is, perhaps, that Since continuing protection has largely provided the outcomes the sports guys now respect we see, indirectly, the original USP delivering.
"24hrs" - symbol? Image? Representation? I see it on non-Byotrol products as shown. As marketing develops more customers will start to assume that it is a necessary component to related products.
Ahh, I am forgetting that the current EPA test is for '24hrs', this new marketing icon that we hear is on the move with various products/suppliers. Recent news may not have much effect on this, perhaps. Rather gives an extra prospect on what is already there and, possibly, combining with a growing interest in safe, non-alcohol sanitizers.
“We have no SCIENTIFIC evidence that they are any better than plain soap and water,” Dr Janet Woodcock Anyone think the EPA test equates to Dr Janet's scientific requirements? She implies she would 'support' such a product. Certainly seems to be a market for this stuff i.e. whether Dr Janet likes it or not. If she wants less ingredients then that must be an advantage for those products with some 'scientific evidence'? Course EPA is not yet done. Stuff happens in this investment world. Had some big losses along with the good times.
Tesco sell 3.5million annually. Boots product is still available in store near me. Rentokil market is modest but they are committed partners. Now EPA [unique] , Solvay cash injected, extended deal over 10 [ten] year agreement, BPR compliant, popular non-alcohol, long lasting, safe hand sanitiser [Kyorin? NHS?] on the list. BTW I see Hargreaves and Lansdown have recently bought in. New investors getting in at fortunate prices. Unfair world. Another halfpenny and I'll be in forgiveness mode. Long term prospects for all, imo. Best execs I've seen in this investing game.
Kills all the bugs other products do and, unlike most if not all such products, continues to do so up to 24hrs, safely without harming human skin. Passes the tests of major plc companies and hopefully the extremely demanding EPA [i.e. Byotrol is not going to have any other product similarly awarded and labelled - discussions going 'through the roof''] If there are other products not so good but good enough and there is an existing market interest in them that's fine for me. Good to hear there is interest usp-wise. However, I don't think there is anything of this quality - any large consumer companies likely to invest do their own stringent tests - we know that most products fail but Byotrol doesn't. The struggle has been not enough money for marketing. So we end up wondering why it would be of interest when some deals don't deliver too well. That said M&S, Tesco, Boots, Beophar, Pets at home, Sainsbury's, the food industry, ISS, outdoor activity types, Rentokil [long standing strong relationship, if low on sales - and to meet EU regs], Solvay [put in real money and doing real marketing] Kyorin [big Japanese company showing keen & varied interest] and more, all seem to see something in the product! Solvay has the marketing budget. Byotrol has some dosh for once and a good strategy. Passing regulations is a money earner. Once confidence increases ..... dyoc.
'Initially Byotrol will pool technical, commercial and sales resource with Solvay Novecare in targeting Products at the EU consumer market. Over time we expect to be expanding into other geographies, into professional markets and in due course into personal care markets too. The two parties will then be sharing gross profit from any jointly developed products.' It is built upon the joint development of anti-microbials, combining the best of Byotrol’s long-lasting antimicrobial formulations and Solvay’s world-leading polymer and surfactant technologies (collectively the “Products”). The Company has already completed (and patented) one such product for the EU consumer market and is actively marketing it jointly with Solvay to customers. Looks like Byotrol is Solvay's choice for a 24 hour product - Mirapol notwithstanding.